Prostate cancer incidence rates in the United States vary significantly across racial and ethnic groups, with Non-Hispanic Black men facing the highest risk. According to recent data, Non-Hispanic Black males have an incidence rate of 194.8 per 100,000 population, which is substantially higher than the overall rate of 120.2 per 100,000. This stark disparity highlights the importance of targeted screening and prevention efforts to address this health inequality. Incidence and mortality trends The burden of prostate cancer in the U.S. has grown in recent years. In 2025, approximately 313,780 men were projected to be diagnosed with prostate cancer, representing a significant increase from previous years. Despite this rising incidence, mortality rates have shown improvement. In 2022, the prostate cancer death rate was 18.7 per 100,000 men, compared to a rate of almost 39 per 100,000 in the year 1990. This decrease reflects advancements in treatment and early detection. Risk factors and survival rates Age remains a critical risk factor for prostate cancer, with men aged 65 to 84 having a 10.6 percent chance of developing the disease. However, there is encouraging news regarding survival rates. From 2014 to 2020, the five-year relative survival rate for prostate cancer patients in the U.S. was an impressive 97 percent. This high survival rate underscores the importance of early detection and the effectiveness of current treatment options.

In 2022, there were 157 cases of prostate cancer per 100,000 population in the state of Louisiana, making it the state with the highest prostate cancer incidence rate that year. This statistic shows the incidence rate of prostate cancer in the U.S. in 2022, by state.

This dataset contains Cancer Incidence data for Prostate Cancer(All Stages^) including: Age-Adjusted Rate, Confidence Interval, Average Annual Count, and Trend field information for US States for the average 5 year span from 2016 to 2020.Data are for males segmented age (All Ages, Ages Under 50, Ages 50 & Over, Ages Under 65, and Ages 65 & Over), with field names and aliases describing the sex and age group tabulated.For more information, visit statecancerprofiles.cancer.govData NotationsState Cancer Registries may provide more current or more local data.TrendRising when 95% confidence interval of average annual percent change is above 0.Stable when 95% confidence interval of average annual percent change includes 0.Falling when 95% confidence interval of average annual percent change is below 0.† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84, 85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.‡ Incidence Trend data come from different sources. Due to different years of data availability, most of the trends are AAPCs based on APCs but some are APCs calculated in SEER*Stat. Please refer to the source for each area for additional information.Rates and trends are computed using different standards for malignancy. For more information see malignant.^ All Stages refers to any stage in the Surveillance, Epidemiology, and End Results (SEER) summary stage.Data Source Field Key(1) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(5) Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2022 submission.(6) Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2022 submission).(7) Source: SEER November 2022 submission.(8) Source: Incidence data provided by the SEER Program. AAPCs are calculated by the Joinpoint Regression Program and are based on APCs. Data are age-adjusted to the 2000 US standard population (19 age groups: <1, 1-4, 5-9, ... , 80-84,85+). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used with SEER November 2022 data.Some data are not available, see Data Not Available for combinations of geography, cancer site, age, and race/ethnicity.Data for the United States does not include data from Nevada.Data for the United States does not include Puerto Rico.

In the period 2019 to 2023, the death rate for prostate cancer among Hispanic Americans was **** per 100,000 population. This statistic shows the death rate for prostate cancer among U.S. males from 2019 to 2023, by race and ethnicity.

ObjectiveUsing the latest cohort study of prostate cancer patients, explore the epidemiological trend and prognostic factors, and develop a new nomogram to predict the specific survival rate of prostate cancer patients.MethodsPatients with prostate cancer diagnosed from January 1, 1975 to December 31, 2019 in the Surveillance, Epidemiology, and End Results Program (SEER) database were extracted by SEER stat software for epidemiological trend analysis. General clinical information and follow-up data were also collected from 105 135 patients with pathologically diagnosed prostate cancer from January 1, 2010 to December 1, 2019. The factors affecting patient-specific survival were analyzed by Cox regression, and the factors with the greatest influence on specific survival were selected by stepwise regression method, and nomogram was constructed. The model was evaluated by calibration plots, ROC curves, Decision Curve Analysis and C-index.ResultsThere was no significant change in the age-adjusted incidence of prostate cancer from 1975 to 2019, with an average annual percentage change (AAPC) of 0.45 (95% CI:-0.87~1.80). Among the tumor grade, the most significant increase in the incidence of G2 prostate cancer was observed, with an AAPC of 2.99 (95% CI:1.47~4.54); the most significant decrease in the incidence of G4 prostate cancer was observed, with an AAPC of -10.39 (95% CI:-13.86~-6.77). Among the different tumor stages, the most significant reduction in the incidence of localized prostate cancer was observed with an AAPC of -1.83 (95% CI:-2.76~-0.90). Among different races, the incidence of prostate cancer was significantly reduced in American Indian or Alaska Native and Asian or Pacific Islander, with an AAPC of -3.40 (95% CI:-3.97~-2.82) and -2.74 (95% CI:-4.14~-1.32), respectively. Among the different age groups, the incidence rate was significantly increased in 15-54 and 55-64 age groups with AAPC of 4.03 (95% CI:2.73~5.34) and 2.50 (95% CI:0.96~4.05), respectively, and significantly decreased in ≥85 age group with AAPC of -2.50 (95% CI:-3.43~-1.57). In addition, age, tumor stage, race, PSA and gleason score were found to be independent risk factors affecting prostate cancer patient-specific survival. Age, tumor stage, PSA and gleason score were most strongly associated with prostate cancer patient-specific survival by stepwise regression screening, and nomogram prediction model was constructed using these factors. The Concordance indexes are 0.845 (95% CI:0.818~0.872) and 0.835 (95% CI:0.798~0.872) for the training and validation sets, respectively, and the area under the ROC curves (AUC) at 3, 6, and 9 years was 0.7 or more for both the training and validation set samples. The calibration plots indicated a good agreement between the predicted and actual values of the model.ConclusionsAlthough there was no significant change in the overall incidence of prostate cancer in this study, significant changes occurred in the incidence of prostate cancer with different characteristics. In addition, the nomogram prediction model of prostate cancer-specific survival rate constructed based on four factors has a high reference value, which helps physicians to correctly assess the patient-specific survival rate and provides a reference basis for patient diagnosis and prognosis evaluation.

To investigate the global incidence of prostate cancer with special attention to the changing age structures. Data regarding the cancer incidence and population statistics were retrieved from the International Agency for Research on Cancer in World Health Organization. Eight developing and developed jurisdictions in Asia and the Western countries were selected for global comparison. Time series were constructed based on the cancer incidence rates from 1988 to 2007. The incidence rate of the population aged ≥ 65 was adjusted by the increasing proportion of elderly population, and was defined as the “aging-adjusted incidence rate”. Cancer incidence and population were then projected to 2030. The aging-adjusted incidence rates of prostate cancer in Asia (Hong Kong, Japan and China) and the developing Western countries (Costa Rica and Croatia) had increased progressively with time. In the developed Western countries (the United States, the United Kingdom and Sweden), we observed initial increases in the aging-adjusted incidence rates of prostate cancer, which then gradually plateaued and even decreased with time. Projections showed that the aging-adjusted incidence rates of prostate cancer in Asia and the developing Western countries were expected to increase in much larger extents than the developed Western countries.

The Prostate Cancer Epidemiology Forecast Report provides incidence/prevalence, diagnosed patient trends, and long-term forecasts across the US, EU5, and Japan (7MM). It highlights disease dynamics, unmet needs, diagnosis rates, and patient landscape evolution, projecting 2,831,314 5-year Prevalent Prostate Cancer Cases in 2025 across the 7MM

In 2023, there were 18.7 deaths from prostate cancer per 100,000 men in the United States. This statistic shows the prostate cancer death rate in the United States from 1975 to 2023.

According to Cognitive Market Research, The Prostate Cancer Therapeutics Market was USD XX Billion in 2023 and is set to achieve a market size of USD XX Billion by the end of 2031 growing at a CAGR of XX% from 2024 to 2031. North America held the major market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX % from 2024 to 2031. The Asia Pacific region is the fastest-growing market with a CAGR of XX% from 2024 to 2031 and it is projected that it will grow at a CAGR of XX% in the future. Europe accounted for a market share of over XX% of the global revenue with a market size of USD XX million. Latin America had a market share for more than XX% of the global revenue with a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. Middle East and Africa had a market share of around XX% of the global revenue and was estimated at a market size of USD XX million in 2024 and will grow at a compound annual growth rate (CAGR) of XX% from 2024 to 2031. The Prostate Cancer Therapeutics Market held the highest market revenue share in 2024.

Market Dynamics of The Prostate Cancer Therapeutics Market

Key Drivers for The Prostate Cancer Therapeutics Market

Growing Prevalence of Prostate Cancer fuels the Growth of the Prostate Cancer Therapeutics Market

The market for Prostate Cancer therapeutics is anticipated to develop in the future due to the Growing incidence of prostate cancer. According to the National Cancer Institute, the National Institute of Health (The U.S.) depicts that out of roughly 200,000 cases that were reported in 2020, there were 34,000 deaths from prostate cancer, representing a mortality rate of 5.5%. The analysis suggests that 12.1% of men are expected to develop prostate cancer in their lifetime. Thus, the mortality rate increased due to the growing prevalence of prostate cancer. For instance, in January 2024, according to the American Cancer Society, a US-based voluntary health organization dedicated to eliminating cancer, it was estimated that there were about 299,010 new cases of prostate cancer and about 35,250 deaths from prostate cancer. About 1 man in 8 will be diagnosed with prostate cancer during his lifetime. Therefore, the rising incidence of cancer is driving the growth of the prostate cancer drugs market. Source:(https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html) Therefore, the rising prevalence of prostate cancer is propelling the growth of the prostate cancer therapeutics market, highlighting the urgent need for effective treatment options.

Biotechnological innovation in prostate cancer treatment drugs to Drive the Global Market of Prostate Cancer Therapeutics.

The market for prostate cancer medications is significantly influenced by the Biotechnological research and development innovation in prostate cancer treatment drugs. Recent developments in prostate cancer therapies have integrated several bioinformatics and computational biology applications to attain the best possible cancer treatment. Market participants have discovered a successful way to develop new cures and treatments with a targeted approach that includes whole-genome sequencing, exome profiling, and proteome profiling. For instance, Biopep Solutions Inc. is a privately owned development-stage biotechnology company that discovers and develops innovative therapeutic products for the treatment of cancers and other diseases. This Canada-based company focuses its efforts on the development of BPS-001, which is a complex, multivalent biologic drug that possesses anti-tumour attributes. There is a huge demand for innovation in the prostate cancer therapeutics market for products that have enhanced survival time, less toxicity, increased progression-free survival, increased efficacy, and lower cost. Source:(https://www.biopeps.com/bps-001-mechanism-of-action/) Therefore, with a growing population of elderly men worldwide, the demand for prostate cancer therapeutics is expected to soar, emphasizing the importance of tailored medical solutions to address this demographic trend.

Restraint Factor for The Prostate Cancer Therapeutics Market

Recurrent/Non-Responsive Prostate Cancer restrains the growth of the Prostate Cancer Therapeutics market.

The challenge of Recurrent/non-re...

In 2023, there were around **** deaths from prostate cancer per 100,000 population in the state of Mississippi, making it the state with the highest prostate cancer death rate that year. This statistic shows the death rate from prostate cancer in the U.S. in 2023, by state.

This dataset contains the raw files exported from the CDC-WONDER database, and selections needed on the CDC-WONDER Multiple Causes of Death database in order to access and replicate our data and findings.

Yearly citation counts for the publication titled "Incidence of Initial Local Therapy Among Men With Lower-Risk Prostate Cancer in the United States".

PurposeAlthough the adverse effects of atrial fibrillation (AF) on cancers have been well reported, the relationship between the AF and the adverse outcomes in prostate cancer (PC) remains inconclusive. This study aimed to explore the prevalence of AF and evaluate the relationship between AF and clinical outcomes in PC patients.MethodsPatients diagnosed with PC between 2008 and 2017 were identified from the National Inpatient Sample database. The trends in AF prevalence were compared among PC patients and their subgroups. Multivariable regression models were used to assess the associations between AF and in-hospital mortality, length of hospital stay, total cost, and other clinical outcomes.Results256,239 PC hospitalizations were identified; 41,356 (83.8%) had no AF and 214,883 (16.2%) had AF. AF prevalence increased from 14.0% in 2008 to 20.1% in 2017 (P 

It was estimated that in 2025 around ******* men in the United States would develop prostate cancer. This statistic depicts the estimated number of new cancer cases among men in the U.S. in 2009 and 2025, by cancer type.

The global Cancer Supportive Care Products market, valued at approximately $XX million in 2025, is projected to experience robust growth, driven by rising cancer incidence rates worldwide and an increasing geriatric population susceptible to the disease. The market's compound annual growth rate (CAGR) of 3.56% from 2025 to 2033 indicates a steady expansion, fueled by advancements in supportive care therapies and a growing awareness of the importance of improving the quality of life for cancer patients. Key drivers include the increasing demand for effective pain management solutions, the development of novel drugs with improved efficacy and safety profiles (such as targeted therapies minimizing side effects), and the expanding adoption of personalized medicine approaches tailored to individual patient needs. Market segmentation reveals a significant contribution from G-CSFs and ESAs, reflecting their crucial role in managing chemotherapy-induced neutropenia and anemia, respectively. However, challenges such as high treatment costs, stringent regulatory approvals, and potential side effects associated with certain supportive care medications represent significant restraints. Geographic analysis suggests that North America and Europe currently hold the largest market shares, owing to well-established healthcare infrastructure and higher healthcare spending. However, rapidly developing economies in Asia Pacific are expected to witness significant growth in the coming years, driven by rising cancer prevalence and increasing healthcare investments in these regions. The competitive landscape is characterized by a mix of established pharmaceutical giants and specialized biotechnology companies, each vying for market share through product innovation, strategic partnerships, and geographic expansion. The market's future trajectory will depend on several factors, including the successful development and launch of innovative supportive care therapies, the implementation of effective healthcare policies aimed at improving cancer care access and affordability, and ongoing research efforts focused on minimizing treatment-related side effects. Expansion into emerging markets and strategic collaborations between pharmaceutical companies and healthcare providers will also play a pivotal role in shaping the market's future. Growth in specific drug classes such as targeted antiemetics and novel pain management solutions will be closely monitored. Furthermore, the evolving regulatory landscape and pricing pressures will influence market dynamics, making proactive adaptation and strategic planning crucial for market players to maintain competitiveness and capitalize on growth opportunities. The increasing focus on patient-centric care and value-based healthcare will further propel the market's growth and influence the development and adoption of supportive care products. Recent developments include: In March 2022, Imugene, based in Australia, reported a new clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to evaluate the safety and efficacy of Imugene's HER-Vaxx, B-cell activating immunotherapy, in combination with MSD's anti-PD-1 therapy, pembrolizumab (KEYTRUDA), in patients with HER-2 positive gastric cancer., In March 2022, Novartis received United States Food and Drug Administration (FDA) approval for Pluvicto for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body (metastatic). These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy).. Key drivers for this market are: Large Number of Side-effects Associated with Cancer Treatment, Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure; Increasing Prevalence of Cancer. Potential restraints include: Large Number of Side-effects Associated with Cancer Treatment, Rising Disposable Incomes and Constant Improvements in Healthcare Infrastructure; Increasing Prevalence of Cancer. Notable trends are: NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Segment is Expected to Register High Growth Over the Forecast Period.

In the period 2018-2019, 2021, it was estimated that U.S. men aged 65 to 84 years and older had a **** percent chance of developing prostate cancer. This statistic shows the probability of males in the United States developing prostate cancer in 2018-2019, 2021, by age.

In 2023, only 30 percent of survey respondents who were aged 50 to 64 years had a prostate-specific antigen (PSA) test that screened for prostate cancer in the past year. Prostate cancer is the most common type of cancer among men in the United States. This statistic shows the percentage of men aged 50 years and older who had a prostate cancer test in the U.S. in the past year as of 2023, by age.

PurposeAlthough the adverse effects of atrial fibrillation (AF) on cancers have been well reported, the relationship between the AF and the adverse outcomes in prostate cancer (PC) remains inconclusive. This study aimed to explore the prevalence of AF and evaluate the relationship between AF and clinical outcomes in PC patients.MethodsPatients diagnosed with PC between 2008 and 2017 were identified from the National Inpatient Sample database. The trends in AF prevalence were compared among PC patients and their subgroups. Multivariable regression models were used to assess the associations between AF and in-hospital mortality, length of hospital stay, total cost, and other clinical outcomes.Results256,239 PC hospitalizations were identified; 41,356 (83.8%) had no AF and 214,883 (16.2%) had AF. AF prevalence increased from 14.0% in 2008 to 20.1% in 2017 (P 

From 2003 to 2017, there were around 485 new cases of prostate cancer per 100,000 men aged 60 to 64 years in the United States. This statistic illustrates the rate of new prostate cancer cases in the United States from 2003 to 2017 by age, per 100,000 men.

Snapshot img

Castration-Resistant Prostate Cancer Treatment Market Size 2024-2028

The castration-resistant prostate cancer treatment market size is forecast to increase by USD 5.98 billion at a CAGR of 8.83% between 2023 and 2028.

The market is experiencing significant growth due to the increasing prevalence of prostate cancer and the evolution of new treatment options. As prostate cancer advances and becomes resistant to hormone therapy, patients require alternative treatment methods. The market is witnessing the development of new proteins and targeted therapies such as cell and gene therapy, which offer improved efficacy and reduced side effects compared to traditional CRPC treatments. However, the use of these advanced therapies comes with health complications, such as cardiovascular events and bone health issues, which can impact patient quality of life and increase healthcare costs. Therefore, there is a growing need for effective management strategies to mitigate these side effects and improve patient outcomes.
In summary, the CRPC treatment market is driven by the rising incidence of prostate cancer and the emergence of innovative treatment options and medical technologies, while challenges include managing the side effects of existing therapies and ensuring patient access to affordable and effective care.

What will be the Size of the Castration-Resistant Prostate Cancer Treatment Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapies designed to manage the advanced stage of prostate cancer that is no longer responsive to traditional hormone therapy. This ailment, characterized by the continued production of testosterone despite castration or medical castration, affects a significant portion of prostate cancer patients. The market dynamics are driven by the increasing incidence of CRPC, which is diagnosed through various methods including PSA testing and prostate biopsy. New treatments, including combination therapies, are emerging to address the unmet needs of this patient population. These new treatments include hormone therapy, targeted therapies such as enzalutamide and abiraterone, and testosterone-lowering therapy.
Regulatory agencies continue to approve these therapies, expanding the treatment landscape for CRPC. Additionally, precision medicine is gaining traction, tailoring therapies to individual patients based on genetic markers. CRPC patients may experience symptoms such as difficulty urinating, weight loss, and shortness of breath, necessitating ongoing healthcare expenditure. The geriatric population, a significant portion of CRPC patients, further complicates treatment approaches due to comorbidities and age-related factors.

How is this CRPC Treatment Industry segmented and which is the largest segment?

The castration-resistant prostate cancer treatment industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

Distribution Channel

  Hospital pharmacies
  Retail pharmacies
  Online pharmacies


Therapy

  Hormonal therapy
  Chemotherapy
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK


  Asia

    China


  Rest of World (ROW)

By Distribution Channel Insights

The hospital pharmacies segment is estimated to witness significant growth during the forecast period.

The market is characterized by the adoption of various therapies, including hormone therapy, surgical castration, medical castration, and new treatments such as combination therapies. Hormone therapy, which includes testosterone-lowering therapy, remains a conventional option for CRPC treatment. Newer treatments, like second-line hormone therapy, chemotherapy, immunotherapy, radiopharmaceutical therapy, and targeted therapy, are gaining popularity due to their efficacy in managing CRPC resistance mechanisms. Personalized medicine and technological integration are driving innovation in CRPC diagnosis and treatment, with diagnostic tools like imaging technologies, genomic testing, and liquid biopsies playing crucial roles. The European market is witnessing significant growth, with oral route and injectable drug delivery methods dominating the distribution channel landscape.

Hospital pharmacies hold the largest market share due to their role in ensuring patient safety and proper medication administration within healthcare facilities. Key players are focusing on clinical trials to develop more effective and less burdensome treatment options, addressing side effects and improving overall patient outcomes.

Get a glance at the Castration-Resistant Prostate Cancer (CRPC) Treatment Industry report of share of various segments. Request Free Sample

The Hospital pharmacies segment was valued at